🧬 PREDIX LumB did not deliver a clear neoadjuvant win for palbociclib over chemotherapy, but that is not the most important finding. In this randomized phase II trial in ER-positive/HER2-negative breast cancer, radiologic response at 12 weeks was 59% with paclitaxel versus 45% with palbociclib plus endocrine therapy, narrowly missing statistical significance. 📊 On the surface, that looks like another setback for neoadjuvant CDK4/6 inhibition. But the real story may be deeper. 🔍 Researchers developed CDKPredX, a 31-gene transcriptomic signature that identified tumors resistant to chemotherapy yet still responsive to palbociclib plus endocrine therapy. Even more importantly, that signal was independently validated in CORALLEEN. ✨ That means PREDIX LumB may not be the trial that changes practice today. ✨ It may be the trial that shows how practice could change tomorrow. In ER+/HER2- breast cancer, the future may not be about giving the same neoadjuvant treatment to everyone. It may be about identifying which tumor truly needs chemotherapy, and which one may not. 🎯 Read our full breakdown on @OncoDailyBreast oncodaily.com/oncolibrary/br… @io_zerdes @carljhartman #BreastCancer #ERPositive #HER2Negative #Palbociclib #CDK46 #PREDIXLumB #CDKPredX #PrecisionOncology #BreastOncology #OncoDailyBreast